---
title: "HROWM.US (HROWM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HROWM.US/news.md"
symbol: "HROWM.US"
name: "HROWM.US"
parent: "https://longbridge.com/en/quote/HROWM.US.md"
datetime: "2026-03-15T02:56:26.284Z"
locales:
  - [en](https://longbridge.com/en/quote/HROWM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HROWM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HROWM.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/HROWM.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/HROWM.US/news.md)


# HROWM.US (HROWM.US) — Related News

### [Harrow Health Updates Investor Presentation via Regulation FD Filing](https://longbridge.com/en/news/278558566.md)
*2026-03-10T12:44:43.000Z*
> Harrow Health has updated its investor presentation through a Regulation FD filing, providing new materials for manageme

### [These Analysts Revise Their Forecasts On Harrow Following Q4 Results](https://longbridge.com/en/news/277796199.md)
*2026-03-04T14:07:35.000Z*
> Harrow Inc. (NASDAQ:HROW) reported mixed Q4 results, with earnings of 17 cents per share, missing estimates, but sales r

### [Harrow Inc. (NASDAQ: HROW) stock falls due to Q4 EPS miss at 17 cents, below 38 cents estimate. Sales rose to $89.09 million from $66.81 million, beating $88.45 million consensus. $8.5 million R&D expense reported for Melt Pharmaceuticals acquisition. Company boasts 700% stock price increase in past five years.](https://longbridge.com/en/news/277663754.md)
*2026-03-03T17:55:13.000Z*
> Harrow Inc. (NASDAQ: HROW) stock fell in premarket trading after reporting Q4 earnings of 17 cents per share, missing th

### [Harrow stock down as Q4 earnings miss estimate. Sales up to $89.09M from $66.81M. $8.5M in R&D expenses. Full article on Benzinga.com.](https://longbridge.com/en/news/277630772.md)
*2026-03-03T13:17:18.000Z*
> Harrow Inc. (NASDAQ: HROW) shares are down in premarket trading following a Q4 earnings report that missed estimates. Th

### [Why Is Eye-Disease-Focused Harrow Stock Falling Today?](https://longbridge.com/en/news/277630900.md)
*2026-03-03T13:11:49.000Z*
> Harrow Inc. (NASDAQ:HROW) shares fell 12.32% to $46.99 in premarket trading after missing earnings expectations with Q4 

### [Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication](https://longbridge.com/en/news/277620504.md)
*2026-03-03T12:29:05.000Z*
### [BUZZ-Drugmaker Harrow slumps after forecasting annual revenue below estimates](https://longbridge.com/en/news/277599920.md)
*2026-03-03T10:02:00.000Z*
### [](https://longbridge.com/en/news/277529297.md)
*2026-03-02T21:42:12.000Z*
> Harrow shares are trading lower after the company reported mixed Q4 financial results and issued FY26 sales guidance bel